Elixinol Wellness Limited (ASX:EXL)
Australia · Delayed Price · Currency is AUD 0.0060
0.00 (0.00%)
Sep 30, 2026, 4:10 PM AEST
Elixinol Wellness Income Statement
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 15.9 | 15.5 | 14.96 | 8.27 | 7.06 | 9.34 | |
Revenue Growth | 6.08% | 3.64% | 80.87% | 17.21% | -24.45% | -37.79% |
Cost of Revenue | 9.13 | 9.79 | 9.6 | 5 | 4.07 | 7.22 |
Gross Profit | 6.76 | 5.71 | 5.36 | 3.27 | 2.99 | 2.12 |
Selling, General & Admin | 8.31 | 9.39 | 8.78 | 8.58 | 12.28 | 18.82 |
Other Operating Expenses | -0.23 | 0.08 | 0.54 | -0.54 | -0.51 | -0.5 |
Operating Expenses | 9.36 | 10.77 | 10.41 | 9.31 | 12.74 | 20 |
Operating Income | -2.6 | -5.06 | -5.05 | -6.04 | -9.75 | -17.89 |
Interest Expense | -0.43 | -0.49 | -0.21 | -0.1 | -0.07 | -0.09 |
Interest & Investment Income | 0.01 | 0.01 | 0.03 | 0.21 | 0.02 | 0.05 |
Currency Exchange Gain (Loss) | -0.23 | -0.23 | 0.01 | -0.01 | -0.04 | 0.08 |
Other Non Operating Income (Expenses) | - | - | - | - | - | -0.33 |
EBT Excluding Unusual Items | -3.26 | -5.77 | -5.22 | -5.94 | -9.84 | -18.18 |
Impairment of Goodwill | -0.04 | - | - | - | - | - |
Gain (Loss) on Sale of Investments | - | - | - | -1.33 | - | - |
Gain (Loss) on Sale of Assets | -0 | 0 | -0 | -0 | 0.03 | -0.08 |
Asset Writedown | -0.29 | -0.27 | -0.09 | -0.24 | -0.77 | -0.75 |
Other Unusual Items | - | - | - | - | 0.01 | 1.92 |
Pretax Income | -4.07 | -6.04 | -5.31 | -7.5 | -10.57 | -17.09 |
Income Tax Expense | -0.54 | -0.54 | -3.59 | 0 | 0 | -0.07 |
Earnings From Continuing Operations | -3.53 | -5.5 | -1.72 | -7.51 | -10.57 | -17.03 |
Earnings From Discontinued Operations | 0.05 | - | - | - | - | - |
Net Income to Company | -3.48 | -5.5 | -1.72 | -7.51 | -10.57 | -17.03 |
Net Income | -3.48 | -5.5 | -1.72 | -7.51 | -10.57 | -17.03 |
Net Income to Common | -3.48 | -5.5 | -1.72 | -7.51 | -10.57 | -17.03 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 352 | 256 | 155 | 59 | 40 | 39 |
Shares Outstanding (Diluted) | 352 | 256 | 155 | 59 | 40 | 39 |
Shares Change | 73.24% | 65.77% | 160.95% | 49.90% | 0.40% | 75.46% |
EPS (Basic) | -0.01 | -0.02 | -0.01 | -0.13 | -0.27 | -0.43 |
EPS (Diluted) | -0.01 | -0.02 | -0.01 | -0.13 | -0.27 | -0.43 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -2.62 | -3.28 | -3.53 | -2.77 | -8.16 | -14.23 |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.02 | -0.05 | -0.21 | -0.36 |
Gross Margin | 42.54% | 36.86% | 35.82% | 39.50% | 42.31% | 22.68% |
Operating Margin | -16.35% | -32.63% | -33.78% | -73.09% | -138.20% | -191.54% |
Profit Margin | -21.88% | -35.48% | -11.51% | -90.79% | -149.84% | -182.32% |
Free Cash Flow Margin | -16.46% | -21.15% | -23.60% | -33.50% | -115.62% | -152.40% |
EBITDA | -2.09 | -4.41 | -4.51 | -5.92 | -9.57 | -17.4 |
EBITDA Margin | -13.12% | -28.43% | -30.17% | -71.60% | -135.69% | -186.33% |
D&A For EBITDA | 0.51 | 0.65 | 0.54 | 0.12 | 0.18 | 0.49 |
EBIT | -2.6 | -5.06 | -5.05 | -6.04 | -9.75 | -17.89 |
EBIT Margin | -16.35% | -32.63% | -33.78% | -73.09% | -138.20% | -191.54% |